LianBio (LIANY)
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses. These include mavacamten, aimed at both obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction. TP-03 is being developed for Demodex blepharitis and meibomian gland dysfunction. For cancer, LianBio is advancing NBTXR3 for head and neck squamous cell carcinoma and other solid tumors, alongside Infigratinib for cholangiocarcinoma (both first-line and second-line settings) and gastric cancers, and BBP-398 also for solid tumors. Furthermore, Omilancor and NX-13 are in development for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other programs include LYR-210 for chronic rhinosinusitis and Sisunatovir to combat respiratory syncytial virus. LianBio has established key collaborations, partnering with Tarsus Pharmaceuticals, Inc. on the development and market introduction of TP-03 specifically for Demodex blepharitis. Additionally, it maintains a strategic alliance with Nanobiotix S.A. for NBTXR3, a novel radioenhancer intended for direct intratumoral injection before conventional radiation therapy. Established in 2019, the company's corporate headquarters are located in Princeton, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
LianBio
No splits on record
Nothing in LIANY's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $801K | $1.33M | $1M | $526K | $76K | $0 |
| Gross Profit | $0 | -$801K | -$1.33M | -$1M | -$526K | -$76K | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $19K | $10.64M | $35.32M | $59.68M | $158.9M | $121.09M | $22.66M |
| Selling, General, and Administrative | $1.25M | $27.42M | $62.9M | $64.52M | $36.88M | $13.93M | $1.72M |
| Other | $0 | $0 | $1K | $0 | -$477K | $0 | $0 |
| Total Operating Expenses | $1.27M | $38.06M | $98.22M | $124.2M | $195.3M | $135.03M | $24.38M |
| Operating Income (EBIT) | -$1.27M | -$38.86M | -$99.54M | -$125.2M | -$195.57M | -$135.1M | -$24.38M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $884K | $4.08M | $13M | $4.32M | $243K | $0 | $11K |
| Other Income (Expense) | $6.18M | $41.31M | $411.13M | $14.71M | -$212K | -$4.74M | $10K |
| Income Before Tax (EBT) | $4.91M | $2.45M | $311.59M | -$110.49M | -$196.04M | -$139.84M | -$24.37M |
| Income Tax Expense | $0 | -$22K | $450K | -$333K | $519K | $4K | $4K |
| Net Income | $4.91M | $2.48M | $311.14M | -$110.16M | -$196.56M | -$139.84M | -$24.37M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | 0.04 | 0.02 | 2.88 | -1.02 | -1.83 | -1.33 | -0.23 |
| Diluted EPS | 0.04 | 0.02 | 2.87 | -1.02 | -1.83 | -1.33 | -0.23 |
| Weighted Average OS | 109.13M | 108.28M | 107.92M | 107.92M | 107.28M | 105.26M | 108.30M |
| EBITDA | -$1.27M | $3.26M | $312.91M | -$109.49M | -$195.52M | -$134.9M | -$24.38M |
| EBITDA Margin | - | - | - | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $9.39M | $51.7M | $438.58M | $79.22M | $228.18M | $254.35M | $43.3M |
| Short-Term Investments | $0 | $0 | $128.79M | $223.14M | $155.06M | $0 | $0 |
| Cash and Short-Term Investments | $9.39M | $51.7M | $567.37M | $302.36M | $383.24M | $254.35M | $43.3M |
| Accounts Receivable | $10.2M | $10.14M | $39.91M | $4.41M | $7.22M | $20.26M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $934K | $1.88M | $6.18M | $1.96M | $1.5M | $1.07M | $0 |
| Total Current Assets | $20.52M | $63.72M | $613.47M | $312.77M | $399.64M | $275.78M | $43.35M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $0 | $0 | $4.43M | $7.09M | $6.64M | $2.53M | $532K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $71K | $73K | $20M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $20K | $54K | $982K | $0 |
| Total Long-Term Assets | $0 | $0 | $4.5M | $7.19M | $26.7M | $3.51M | $532K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $20.52M | $63.72M | $617.96M | $319.96M | $426.33M | $279.29M | $43.88M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $0 | $155K | $4.02M | $1.45M | $3.23M | $4.33M | $0 |
| Short-Term Debt | $0 | $0 | $1.95M | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $14K | $704K | $30.07M | $8.32M | $3.07M | $1.12M | -$14 |
| Total Current Liabilities | $14K | $859K | $36.03M | $23.62M | $15.09M | $6.23M | $3.34M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $226K | $210K | $20.21M | $20M | $0 |
| Total Long-Term Liabilities | $0 | $0 | $737K | $2.7M | $23.91M | $21.34M | $350K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $14K | $859K | $36.77M | $26.31M | $39.01M | $27.57M | $3.69M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $349.79M | $55M |
| Common Stock | $2K | $2K | $2K | $2K | $2K | $0 | $0 |
| Retained Earnings | -$151.74M | -$156.64M | -$159.12M | -$470.53M | -$360.23M | -$163.94M | -$24.33M |
| Comprehensive Income & Other | $27.58M | $27.58M | -$2.03M | -$2.08M | $526K | -$40K | $0 |
| Other Stockholders' Equity | $172.25M | $219.51M | $740.31M | $730.4M | $713.78M | $380.88M | $63.52M |
| Total Equity | $20.51M | $62.87M | $581.2M | $259.87M | $353.55M | $216.95M | $39.18M |
| Minority Interest | $0 | $0 | $0 | $33.77M | $33.77M | $34.77M | $999K |
| Total Liabilities and Equity | $20.52M | $63.72M | $617.96M | $286.19M | $392.56M | $244.51M | $42.88M |
| Supplementary Data | |||||||
| Total Debt | $0 | $0 | $2.46M | $4.34M | $4.83M | $1.88M | $532K |
| Net Debt | -$9.39M | -$51.7M | -$436.13M | -$74.88M | -$223.34M | -$252.47M | -$42.77M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | $4.91M | $2.48M | $311.14M | -$110.16M | -$196.56M | -$139.84M | -$24.37M |
| Depreciation & Amortization | $0 | $801K | $1.33M | $1.01M | $526K | $76K | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $0 | $0 | $0 | $19.15M | $8.66M | $5.18M | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$66K | $29.79M | -$38.11M | -$1.4M | $14.23M | -$20.03M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$155K | -$3.86M | $2.58M | -$1.7M | -$1.71M | $4.17M | $0 |
| Other Working Capital | $262K | -$25.46M | $12.2M | $11.09M | $1.28M | $16.03M | $3.12M |
| Total Working Capital Change | $40K | $469K | -$23.33M | $7.99M | $13.8M | $171K | $3.12M |
| Other Non-Cash Items | $1 | $1 | -$30.2M | -$17.05M | $9.4M | $36.11M | $9.53M |
| Net Cash from Operating | $4.95M | $3.75M | $258.94M | -$99.07M | -$164.17M | -$98.31M | -$11.72M |
| Investing Activities | |||||||
| Capital Expenditures | $0 | $0 | -$375K | -$1.84M | -$948K | -$888K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | -$148.49M | -$302.78M | -$155.2M | $0 | $0 |
| Sales of Investments | $0 | $128.85M | $248.18M | $235.5M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $128.85M | $99.31M | -$69.12M | -$156.14M | -$888K | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | -$15M | - |
| Common Stock Issuance | $0 | $0 | $1.78M | $1.71M | $311.08M | $295.3M | $55.09M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$47.38M | -$550.7M | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $0 | $0 | -$394K | -$14.71M | $55.09M |
| Net Cash from Financing | -$47.38M | -$550.7M | $1.78M | $1.71M | $313.69M | $310.29M | $55.09M |
| Forex Effect | $112K | $31.21M | -$664K | $17.52M | -$19.55M | $325K | $0 |
| Net Change in Cash | -$42.32M | -$386.88M | $359.36M | -$148.96M | -$26.17M | $211.05M | $43.37M |
| Supplementary Data | |||||||
| Operating Cash Flow | $4.95M | $3.75M | $258.94M | -$99.07M | -$164.17M | -$98.31M | -$11.72M |
| Capital Expenditure | $1 | $2 | -$375K | -$1.84M | -$948K | -$888K | $0 |
| Free Cash Flow | $4.95M | $3.75M | $258.56M | -$100.91M | -$165.12M | -$99.2M | -$11.72M |
| Cash at Beginning | $51.7M | $438.58M | $79.22M | $228.18M | $254.35M | $43.3M | -$75K |
| Cash at End | $9.39M | $51.7M | $438.58M | $79.22M | $228.18M | $254.35M | $43.3M |